SK283137B6 - Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy - Google Patents

Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy Download PDF

Info

Publication number
SK283137B6
SK283137B6 SK764-99A SK76499A SK283137B6 SK 283137 B6 SK283137 B6 SK 283137B6 SK 76499 A SK76499 A SK 76499A SK 283137 B6 SK283137 B6 SK 283137B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
composition according
mannitol
halogen
drying
Prior art date
Application number
SK764-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK76499A3 (en
Inventor
Chris Bland
Gerald Steele
Original Assignee
Astra Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharmaceuticals Ltd. filed Critical Astra Pharmaceuticals Ltd.
Publication of SK76499A3 publication Critical patent/SK76499A3/sk
Publication of SK283137B6 publication Critical patent/SK283137B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK764-99A 1996-12-20 1997-12-11 Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy SK283137B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying

Publications (2)

Publication Number Publication Date
SK76499A3 SK76499A3 (en) 1999-11-08
SK283137B6 true SK283137B6 (sk) 2003-03-04

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
SK764-99A SK283137B6 (sk) 1996-12-20 1997-12-11 Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy

Country Status (36)

Country Link
US (1) US6114313A (es)
EP (1) EP1007094B1 (es)
JP (1) JP4488538B2 (es)
KR (1) KR100552880B1 (es)
CN (1) CN1121875C (es)
AR (1) AR010377A1 (es)
AT (1) ATE221787T1 (es)
AU (1) AU758857B2 (es)
BR (1) BR9713974B1 (es)
CA (1) CA2275153C (es)
CZ (1) CZ300635B6 (es)
DE (1) DE69714616T2 (es)
DK (1) DK1007094T3 (es)
EE (1) EE03857B1 (es)
ES (1) ES2182133T3 (es)
FR (1) FR15C0060I2 (es)
HK (1) HK1026366A1 (es)
HU (1) HU226616B1 (es)
ID (1) ID21635A (es)
IL (1) IL130449A0 (es)
IS (1) IS1897B (es)
MY (1) MY121982A (es)
NO (1) NO327142B1 (es)
NZ (1) NZ336027A (es)
PL (1) PL190493B1 (es)
PT (1) PT1007094E (es)
RU (1) RU2205012C2 (es)
SA (1) SA97180719B1 (es)
SE (1) SE9604795D0 (es)
SI (1) SI1007094T1 (es)
SK (1) SK283137B6 (es)
TR (1) TR199901412T2 (es)
TW (1) TW522015B (es)
UA (1) UA66779C2 (es)
WO (1) WO1998028009A1 (es)
ZA (1) ZA9711055B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
BR112015022070B1 (pt) 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
CA2971868C (en) 2015-01-14 2023-04-04 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
US11260071B2 (en) 2017-06-23 2022-03-01 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (es) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Atp凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition

Also Published As

Publication number Publication date
EE03857B1 (et) 2002-10-15
CN1240362A (zh) 2000-01-05
HK1026366A1 (en) 2000-12-15
PL190493B1 (pl) 2005-12-30
DE69714616T2 (de) 2003-04-03
PL334006A1 (en) 2000-01-31
US6114313A (en) 2000-09-05
TR199901412T2 (xx) 1999-08-23
NO327142B1 (no) 2009-05-04
KR20000069598A (ko) 2000-11-25
JP4488538B2 (ja) 2010-06-23
CA2275153A1 (en) 1998-07-02
CA2275153C (en) 2008-03-25
ATE221787T1 (de) 2002-08-15
HUP0000572A2 (hu) 2001-05-28
EE9900260A (et) 2000-02-15
FR15C0060I1 (es) 2015-10-23
CN1121875C (zh) 2003-09-24
JP2001507022A (ja) 2001-05-29
IS1897B (is) 2003-10-20
IL130449A0 (en) 2000-06-01
FR15C0060I2 (fr) 2016-04-22
ES2182133T3 (es) 2003-03-01
TW522015B (en) 2003-03-01
SI1007094T1 (en) 2003-02-28
SE9604795D0 (sv) 1996-12-20
NO993067D0 (no) 1999-06-21
DK1007094T3 (da) 2002-10-28
WO1998028009A1 (en) 1998-07-02
BR9713974B1 (pt) 2010-02-23
RU2205012C2 (ru) 2003-05-27
ID21635A (id) 1999-07-08
NO993067L (no) 1999-08-09
EP1007094A1 (en) 2000-06-14
MY121982A (en) 2006-03-31
PT1007094E (pt) 2002-12-31
HU226616B1 (en) 2009-04-28
ZA9711055B (en) 1998-07-08
SA97180719B1 (ar) 2006-05-13
DE69714616D1 (de) 2002-09-12
HUP0000572A3 (en) 2002-10-28
IS5064A (is) 1999-06-03
EP1007094B1 (en) 2002-08-07
AU5351598A (en) 1998-07-17
UA66779C2 (uk) 2004-06-15
AU758857B2 (en) 2003-04-03
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
NZ336027A (en) 2001-03-30
CZ220199A3 (cs) 1999-11-17
BR9713974A (pt) 2000-04-11
AR010377A1 (es) 2000-06-07
CZ300635B6 (cs) 2009-07-08

Similar Documents

Publication Publication Date Title
JP3576180B2 (ja) 改良イフォスファミド凍結乾燥組成物
SK283137B6 (sk) Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy
PT725642E (pt) Prostaglandina e 1 estabilizada
EP1000079B1 (en) New formulation
FI83476C (fi) Foerfarande foer framstaellning av en beredning av 7 -difluorometyltioacetamido-7 -metoxi-3-/1-(2 -hydroxialkyl)-1h-tetrazol-5-yl/tiometyl-1-detia-1-oxa-3-cefem-4 -karboxisyra.
SK280840B6 (sk) Lyofilizovaný prípravok obsahujúci 1,1',1''-fosfinotioylidíntrisaziridín a spôsob jeho výroby
MXPA99005664A (es) Composiciones farmaceuticas para liofilizacion
AU2003257524B2 (en) New formulation
JPS61130223A (ja) 抗菌性凍結乾燥製剤

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20171211